	US 12,134,643 B2
	Compositions for treatment of disorders
Karen Bannister, Cambridge (GB); Ulla Lashmar, London (GB); Daniel Pettit, Billingham (GB); and Thomas Sandal, Cambridge (GB)
Assigned to CRESCENDO BIOLOGICS LIMITED, Cambridge (GB)
Filed by CRESCENDO BIOLOGICS LIMITED, Cambridge (GB)
Filed on Feb. 5, 2021, as Appl. No. 17/169,182.
Application 17/169,182 is a continuation of application No. 16/316,925, granted, now 10,947,308, previously published as PCT/GB2017/052021, filed on Jul. 10, 2017.
Claims priority of application No. 1612043 (GB), filed on Jul. 11, 2016.
Prior Publication US 2021/0261655 A1, Aug. 26, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/10 (2017.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 39/395 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 47/34 (2017.01); C07K 16/24 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/244 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 39/3955 (2013.01); A61K 39/39591 (2013.01); A61K 47/10 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61K 47/34 (2013.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01)]

20 Claims

1. A composition, comprising:

a) at least one single variable heavy chain domain antibody capable of binding human IL-17A, wherein said single variable heavy chain domain antibody comprises a CDR1 having SEQ ID NO: 2, a CDR2 having SEQ ID NO: 3 and a CDR3 having SEQ ID NO: 4,

b) 10-150 mM Tris/glycine,

c) 0.1-150 mM L-arginine/glutamic acid, and

d) 0.1-30% propylene glycol, and optionally 0.1-15% sorbitol, and

wherein the pH of said composition is about 5 to about 9.